Invention Grant
- Patent Title: Human monoclonal antibodies to ganglioside GD2
-
Application No.: US15839391Application Date: 2017-12-12
-
Publication No.: US10906988B2Publication Date: 2021-02-02
- Inventor: Wolfgang Scholz , Ritsuko Sawada
- Applicant: BioNTech Research and Development, Inc.
- Applicant Address: US NY New York
- Assignee: BioNTech Research and Development, Inc.
- Current Assignee: BioNTech Research and Development, Inc.
- Current Assignee Address: US NY New York
- Agency: Choate, Hall & Stewart LLP
- Agent Brenda Herschbach Jarrell; Janet M. Tse
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61K39/395 ; A61K45/06 ; G01N33/574 ; A61K39/00

Abstract:
The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
Public/Granted literature
- US20180346597A1 HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2 Public/Granted day:2018-12-06
Information query